Bellerophon
Therapeutics LLC (Nasdaq: BLPH) reported upbeat interim results from a
Phase 2 long-term extension study of INOplus to treat pulmonary arterial
hypertension. The stock price leaped $2.50 to $6.22.
Upbeat interim study results for Bellerophon Therapeutics
September 25, 2015 at 15:40 PM EDT